Abstract
Background:
Human kallikrein-related peptidase 6 (KLK6) is a member of the kallikrein family of serine proteases. KLK6 is synthesized as a preproenzyme, mainly in tissues of the central nervous system (CNS), and secreted as an inactive precursor. Serum KLK6 is a biomarker of unfavorable prognosis for ovarian cancer, but its sensitivity for early detection is relatively low. Differential glycosylation of KLK6 has been identified in ascites fluid obtained from ovarian cancer patients, suggesting the presence of unique KLK6 isoforms in biological samples.
Methods:
In the present study, we applied a two-step enrichment approach for KLK6 in ovarian cancer ascites, followed by mice immunization and production of monoclonal antibodies. Immunoaffinity techniques coupled to mass spectrometric methods were employed for hybridoma screening and target antigen identification.
Results:
We found that the main target of the newly-generated monoclonal antibodies target was the serine protease inhibitor α1-antitrypsin (A1AT). Additional experiments confirmed that A1AT is the main inhibitor of KLK6 in biological fluids. One new antibody (24ED138) was chosen to build a hybrid assay for the accurate quantification of the A1AT-KLK6 complex in biological samples. The aforementioned assay was evaluated with serum samples collected from patients with ovarian cancer (n=24) and normal donors (n=16) and showed slight improvement in sensitivity (~12%) compared to the standard in-house KLK6 assay.
Conclusions:
We conclude that KLK6 is present in biological fluids either as free form, or bound to A1AT, and the bound form performs better than total KLK6 as a biomarker of ovarian carcinoma.
Acknowledgments
We thank Ilijana Begcevic for technical assistance.
Author contributions: E.P.D. and D.K. designed the research project; D.K. performed all experiments; A.S. performed immunoassays; D.K. wrote the manuscript, and all authors contributed to the revision of the manuscript. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Rawlings ND, Barrett AJ, Finn R. Twenty years of the MEROPS database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res 2016;44:D343–50.10.1093/nar/gkv1118Search in Google Scholar PubMed PubMed Central
2. Harvey TJ, Hooper JD, Myers SA, Stephenson SA, Ashworth LK, Clements JA. Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J Biol Chem 2000;275:37397–406.10.1074/jbc.M004525200Search in Google Scholar PubMed
3. Yousef GM, Chang A, Scorilas A, Diamandis EP. Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun 2000;276: 125–33.10.1006/bbrc.2000.3448Search in Google Scholar PubMed
4. Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007;53:1423–32.10.1373/clinchem.2007.088104Search in Google Scholar PubMed
5. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004;4:876–90.10.1038/nrc1474Search in Google Scholar PubMed
6. Sotiropoulou G, Pampalakis G, Diamandis EP. Functional roles of human kallikrein-related peptidases. J Biol Chem 2009;284:32989–94.10.1074/jbc.R109.027946Search in Google Scholar PubMed PubMed Central
7. Bayani J, Diamandis EP. The physiology and pathobiology of human kallikrein-related peptidase 6 (KLK6). Clin Chem Lab Med 2012;50:211–33.10.1515/cclm.2011.750Search in Google Scholar PubMed
8. Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 1996;2:624–36.10.1007/BF03401646Search in Google Scholar
9. Kurlender L, Borgono C, Michael IP, Obiezu C, Elliott MB, Yousef GM, et al. A survey of alternative transcripts of human tissue kallikrein genes. Biochim Biophys Acta 2005;1755:1–14.10.1016/j.bbcan.2005.02.001Search in Google Scholar PubMed
10. Pampalakis G, Kurlender L, Diamandis EP, Sotiropoulou G. Cloning and characterization of novel isoforms of the human kallikrein 6 gene. Biochem Biophys Res Commun 2004;320:54–61.10.1016/j.bbrc.2004.04.205Search in Google Scholar PubMed
11. Yamashiro K, Tsuruoka N, Kodama S, Tsujimoto M, Yamamura Y, Tanaka T, et al. Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain. Biochim Biophys Acta 1997;1350:11–4.10.1016/S0167-4781(96)00187-XSearch in Google Scholar
12. Yousef GM, Borgono CA, White NM, Robb JD, Michael IP, Oikonomopoulou K, et al. In silico analysis of the human kallikrein gene 6. Tumour Biol 2004;25:282–9.10.1159/000081393Search in Google Scholar PubMed
13. Gomis-Ruth FX, Bayes A, Sotiropoulou G, Pampalakis G, Tsetsenis T, Villegas V, et al. The structure of human prokallikrein 6 reveals a novel activation mechanism for the kallikrein family. J Biol Chem 2002;277:27273–81.10.1074/jbc.M201534200Search in Google Scholar PubMed
14. Petraki CD, Karavana VN, Skoufogiannis PT, Little SP, Howarth DJ, Yousef GM, et al. The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. J Histochem Cytochem 2001;49:1431–41.10.1177/002215540104901111Search in Google Scholar PubMed
15. Ashby EL, Kehoe PG, Love S. Kallikrein-related peptidase 6 in Alzheimer’s disease and vascular dementia. Brain Res 2010;1363:1–10.10.1016/j.brainres.2010.09.017Search in Google Scholar PubMed
16. Ogawa K, Yamada T, Tsujioka Y, Taguchi J, Takahashi M, Tsuboi Y, et al. Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer’s disease and Parkinson’s disease. Psychiatry Clin Neurosci 2000;54:419–26.10.1046/j.1440-1819.2000.00731.xSearch in Google Scholar PubMed
17. Hebb AL, Bhan V, Wishart AD, Moore CS, Robertson GS. Human kallikrein 6 cerebrospinal levels are elevated in multiple sclerosis. Curr Drug Discov Technol 2010;7:137–40.10.2174/157016310793180611Search in Google Scholar PubMed
18. Pampalakis G, Sykioti VS, Ximerakis M, Stefanakou-Kalakou I, Melki R, Vekrellis K, et al. KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species. Oncotarget 2017;8:14502–15.10.18632/oncotarget.13264Search in Google Scholar PubMed PubMed Central
19. Ximerakis M, Pampalakis G, Roumeliotis TI, Sykioti VS, Garbis SD, Stefanis L, et al. Resistance of naturally secreted alpha-synuclein to proteolysis. FASEB J 2014;28:3146–58.10.1096/fj.13-245852Search in Google Scholar PubMed
20. Spencer B, Valera E, Rockenstein E, Trejo-Morales M, Adame A, Masliah E. A brain-targeted, modified neurosin (kallikrein-6) reduces alpha-synuclein accumulation in a mouse model of multiple system atrophy. Mol Neurodegener 2015;10:48.10.1186/s13024-015-0043-6Search in Google Scholar PubMed PubMed Central
21. Kountourakis P, Psyrri A, Scorilas A, Camp R, Markakis S, Kowalski D, et al. Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA). Cancer Sci 2008;99:2224–9.10.1111/j.1349-7006.2008.00942.xSearch in Google Scholar PubMed
22. Ni X, Zhang W, Huang KC, Wang Y, Ng SK, Mok SC, et al. Characterisation of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer 2004;91:725–31.10.1038/sj.bjc.6602041Search in Google Scholar PubMed PubMed Central
23. White NM, Mathews M, Yousef GM, Prizada A, Fontaine D, Ghatage P, et al. Human kallikrein related peptidases 6 and 13 in combination with CA125 is a more sensitive test for ovarian cancer than CA125 alone. Cancer Biomark 2009;5:279–87.10.3233/CBM-2009-0113Search in Google Scholar PubMed
24. White NM, Mathews M, Yousef GM, Prizada A, Popadiuk C, Dore JJ. KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma. Br J Cancer 2009;101:1107–13.10.1038/sj.bjc.6605280Search in Google Scholar PubMed PubMed Central
25. Diamandis EP, Scorilas A, Fracchioli S, Van Gramberen M, De Bruijn H, Henrik A, et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 2003;21:1035–43.10.1200/JCO.2003.02.022Search in Google Scholar PubMed
26. Shan SJ, Scorilas A, Katsaros D, Diamandis EP. Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects. Br J Cancer 2007;96:362–72.10.1038/sj.bjc.6603556Search in Google Scholar PubMed PubMed Central
27. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005;99:267–77.10.1016/j.ygyno.2005.06.040Search in Google Scholar PubMed
28. Kuzmanov U, Jiang N, Smith CR, Soosaipillai A, Diamandis EP. Differential N-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system. Mol Cell Proteomics 2009;8:791–8.10.1074/mcp.M800516-MCP200Search in Google Scholar PubMed PubMed Central
29. Kuzmanov U, Smith CR, Batruch I, Soosaipillai A, Diamandis A, Diamandis EP. Separation of kallikrein 6 glycoprotein subpopulations in biological fluids by anion-exchange chromatography coupled to ELISA and identification by mass spectrometry. Proteomics 2012;12:799–809.10.1002/pmic.201100371Search in Google Scholar PubMed
30. Anderson NL. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845–67.10.1074/mcp.A300001-MCP200Search in Google Scholar
31. Korbakis D, Prassas I, Brinc D, Batruch I, Krastins B, Lopez MF, et al. Delineating monoclonal antibody specificity by mass spectrometry. J Proteomics 2015;114:115–24.10.1016/j.jprot.2014.11.004Search in Google Scholar
32. Csanky E, Olivova P, Rajnavolgyi E, Hempel W, Tardieu N, Katalin ET, et al. Monoclonal antibody proteomics: discovery and prevalidation of chronic obstructive pulmonary disease biomarkers in a single step. Electrophoresis 2007;28:4401–6.10.1002/elps.200700256Search in Google Scholar
33. Diamandis EP, Yousef GM, Soosaipillai AR, Grass L, Porter A, Little S, et al. Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clin Biochem 2000;33:369–75.10.1016/S0009-9120(00)00145-4Search in Google Scholar
34. Christopoulos TK, Diamandis EP. Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. Anal Chem 1992;64:342–6.10.1021/ac00028a004Search in Google Scholar PubMed
35. Korbakis D, Brinc D, Schiza C, Soosaipillai A, Jarvi K, Drabovich AP, et al. Immunocapture-selected reaction monitoring screening facilitates the development of ELISA for the measurement of native TEX101 in biological fluids. Mol Cell Proteomics 2015;14:1517–26.10.1074/mcp.M114.047571Search in Google Scholar PubMed PubMed Central
36. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008;26:1367–72.10.1038/nbt.1511Search in Google Scholar PubMed
37. Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods 2016;13:731–40.10.1038/nmeth.3901Search in Google Scholar PubMed
38. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995;57:289–300.10.1111/j.2517-6161.1995.tb02031.xSearch in Google Scholar
39. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116–21.10.1073/pnas.091062498Search in Google Scholar PubMed PubMed Central
40. Karakosta TD, Soosaipillai A, Diamandis EP, Batruch I, Drabovich AP. Quantification of human kallikrein-related peptidases in biological fluids by multiplatform targeted mass spectrometry assays. Mol Cell Proteomics 2016;15:2863–76.10.1074/mcp.M115.057695Search in Google Scholar PubMed PubMed Central
41. Hutchinson S, Luo LY, Yousef GM, Soosaipillai A, Diamandis EP. Purification of human kallikrein 6 from biological fluids and identification of its complex with alpha(1)-antichymotrypsin. Clin Chem 2003;49:746–51.10.1373/49.5.746Search in Google Scholar PubMed
42. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30.10.3322/caac.21332Search in Google Scholar PubMed
43. Leung F, Diamandis EP, Kulasingam V. From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade. Biomark Med 2012;6:613–25.10.2217/bmm.12.70Search in Google Scholar PubMed
44. Leung F, Bernardini MQ, Brown MD, Zheng Y, Molina R, Bast RC Jr, et al. Validation of a novel biomarker panel for the detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2016;25:1333–40.10.1158/1055-9965.EPI-15-1299Search in Google Scholar PubMed PubMed Central
45. Oikonomopoulou K, Batruch I, Smith CR, Soosaipillai A, Diamandis EP, Hollenberg MD. Functional proteomics of kallikrein-related peptidases in ovarian cancer ascites fluid. Biol Chem 2010;391:381–90.10.1515/bc.2010.045Search in Google Scholar PubMed
46. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222–6.Search in Google Scholar
47. Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Stenman UH. Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. Clin Chem 1999;45:814–21.10.1093/clinchem/45.6.814Search in Google Scholar
Supplemental Material:
The online version of this article (DOI: https://doi.org/10.1515/cclm-2017-0017) offers supplementary material, available to authorized users.
©2017 Walter de Gruyter GmbH, Berlin/Boston
